$823 Million is the total value of Casdin Capital, LLC's 36 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 31.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | LOXO ONCOLOGY INC | $61,499,000 | -1.5% | 360,000 | 0.0% | 7.48% | -14.4% | |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $58,545,000 | +45.2% | 750,000 | +18.1% | 7.12% | +26.2% |
| MYOK | Buy | MYOKARDIA INC | $52,486,000 | +35.5% | 805,000 | +3.2% | 6.38% | +17.8% |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $44,712,000 | +45.5% | 579,776 | +58.9% | 5.43% | +26.5% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $44,070,000 | +12.6% | 312,000 | +24.8% | 5.36% | -2.1% |
| BLFS | Buy | BIOLIFE SOLUTIONS INC | $42,500,000 | +272.5% | 2,428,571 | +142.9% | 5.17% | +223.7% |
| FATE | Sell | FATE THERAPEUTICS INC | $41,540,000 | +40.9% | 2,550,000 | -1.9% | 5.05% | +22.5% |
| NVTA | New | INVITAE CORP | $40,152,000 | – | 2,400,000 | +100.0% | 4.88% | – |
| BLUE | Buy | BLUEBIRD BIO INC | $37,668,000 | +20.0% | 258,000 | +29.0% | 4.58% | +4.3% |
| ONCE | Buy | SPARK THERAPEUTICS INC | $36,821,000 | -3.9% | 675,000 | +45.8% | 4.48% | -16.5% |
| CDXS | CODEXIS INC | $34,729,000 | +19.1% | 2,025,000 | 0.0% | 4.22% | +3.5% | |
| SGMO | Buy | SANGAMO THERAPEUTICS INC | $33,900,000 | +70.5% | 2,000,000 | +42.9% | 4.12% | +48.2% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $27,032,000 | -1.6% | 2,250,818 | +10.6% | 3.29% | -14.5% |
| ILMN | ILLUMINA INC | $26,245,000 | +31.4% | 71,500 | 0.0% | 3.19% | +14.2% | |
| GNMK | Buy | GENMARK DIAGNOSTICS INC | $25,725,000 | +18.6% | 3,500,000 | +2.9% | 3.13% | +3.1% |
| BOLD | Buy | AUDENTES THERAPEUTICS INC | $24,744,000 | +43.9% | 625,000 | +38.9% | 3.01% | +25.0% |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $23,630,000 | -11.1% | 270,000 | 0.0% | 2.87% | -22.8% | |
| VYGR | VOYAGER THERAPEUTICS INC | $21,474,000 | -3.2% | 1,135,000 | 0.0% | 2.61% | -15.9% | |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $16,720,000 | -22.9% | 440,000 | -8.3% | 2.03% | -33.0% |
| EVH | EVOLENT HEALTH INCcl a | $15,620,000 | +34.9% | 550,000 | 0.0% | 1.90% | +17.2% | |
| EDIT | Buy | EDITAS MEDICINE INC | $14,637,000 | +129.1% | 460,000 | +157.9% | 1.78% | +99.0% |
| BGNE | BEIGENE LTDsponsored adr | $12,055,000 | +12.0% | 70,000 | 0.0% | 1.46% | -2.7% | |
| GRTS | New | GRITSTONE ONCOLOGY INC | $10,261,000 | – | 720,586 | +100.0% | 1.25% | – |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $9,757,000 | -24.5% | 220,000 | 0.0% | 1.19% | -34.4% | |
| CNST | New | CONSTELLATION PHARMCETICLS I | $8,848,000 | – | 1,314,743 | +100.0% | 1.08% | – |
| OSUR | Sell | ORASURE TECHNOLOGIES INC | $8,111,000 | -23.1% | 525,000 | -18.0% | 0.99% | -33.1% |
| FIXX | Buy | HOMOLOGY MEDICINES INC | $8,001,000 | +241.0% | 350,000 | +204.3% | 0.97% | +196.3% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $6,902,000 | -31.0% | 235,000 | +6.8% | 0.84% | -40.0% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $6,460,000 | – | 40,000 | +100.0% | 0.78% | – |
| CDNA | CAREDX INC | $5,770,000 | +135.7% | 200,000 | 0.0% | 0.70% | +105.0% | |
| NEOG | NEOGEN CORP | $4,649,000 | -10.8% | 65,000 | 0.0% | 0.56% | -22.5% | |
| CELG | New | CELGENE CORPcall | $4,475,000 | – | 50,000 | +100.0% | 0.54% | – |
| GILD | New | GILEAD SCIENCES INCcall | $3,861,000 | – | 50,000 | +100.0% | 0.47% | – |
| CTMX | CYTOMX THERAPEUTICS INC | $3,839,000 | -19.1% | 207,500 | 0.0% | 0.47% | -29.6% | |
| NTGN | NEON THERAPEUTICS INC | $2,889,000 | -32.2% | 338,345 | 0.0% | 0.35% | -41.1% | |
| JNCE | JOUNCE THERAPEUTICS INC | $2,438,000 | -15.1% | 375,000 | 0.0% | 0.30% | -26.4% | |
| BPMC | Exit | BLUEPRINT MEDICINES CORPcall | $0 | – | -10,000 | -100.0% | -0.09% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INput | $0 | – | -50,000 | -100.0% | -0.32% | – |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -135,000 | -100.0% | -0.44% | – |
| LOXO | Exit | LOXO ONCOLOGY INCput | $0 | – | -20,000 | -100.0% | -0.48% | – |
| FMI | Exit | FOUNDATION MEDICINE INC | $0 | – | -685,000 | -100.0% | -13.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.